Literature DB >> 22968713

Decavanadate, decaniobate, tungstate and molybdate interactions with sarcoplasmic reticulum Ca(2+)-ATPase: quercetin prevents cysteine oxidation by vanadate but does not reverse ATPase inhibition.

Gil Fraqueza1, Luís A E Batista de Carvalho, M Paula M Marques, Luisa Maia, C André Ohlin, William H Casey, Manuel Aureliano.   

Abstract

Recently we demonstrated that the decavanadate (V(10)) ion is a stronger Ca(2+)-ATPase inhibitor than other oxometalates, such as the isoelectronic and isostructural decaniobate ion, and the tungstate and molybdate monomer ions, and that it binds to this protein with a 1 : 1 stoichiometry. The V(10) interaction is not affected by any of the protein conformations that occur during the process of calcium translocation (i.e. E1, E1P, E2 and E2P) (Fraqueza et al., J. Inorg. Biochem., 2012). In the present study, we further explore this subject, and we can now show that the decaniobate ion, [Nb(10) = Nb(10)O(28)](6-), is a useful tool in deducing the interaction and the non-competitive Ca(2+)-ATPase inhibition by the decavanadate ion [V(10) = V(10)O(28)](6-). Moreover, decavanadate and vanadate induce protein cysteine oxidation whereas no effects were detected for the decaniobate, tungstate or molybdate ions. The presence of the antioxidant quercetin prevents cysteine oxidation, but not ATPase inhibition, by vanadate or decavanadate. Definitive V(IV) EPR spectra were observed for decavanadate in the presence of sarcoplasmic reticulum Ca(2+)-ATPase, indicating a vanadate reduction at some stage of the protein interaction. Raman spectroscopy clearly shows that the protein conformation changes that are induced by V(10), Nb(10) and vanadate are different from the ones induced by molybdate and tungstate monomer ions. Here, Mo and W cause changes similar to those by phosphate, yielding changes similar to the E1P protein conformation. The putative reduction of vanadium(V) to vanadium(IV) and the non-competitive binding of the V(10) and Nb(10) decametalates may explain the differences in the Raman spectra compared to those seen in the presence of molybdate or tungstate. Putting it all together, we suggest that the ability of V(10) to inhibit the Ca(2+)-ATPase may be at least in part due to the process of vanadate reduction and associated protein cysteine oxidation. These results contribute to the understanding and application of these families of mono- and polyoxometalates as effective modulators of many biological processes, particularly those associated with calcium homeostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968713     DOI: 10.1039/c2dt31688a

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  10 in total

1.  Cytotoxic, hematologic and histologic effects of niobium pentoxide in Swiss mice.

Authors:  Nuha Ahmad Dsouki; Maurício Pereira de Lima; Roseli Corazzini; Thaís Moura Gáscon; Ligia Ajaime Azzalis; Virgínia Berlanga Campos Junqueira; David Feder; Fernando Luiz Affonso Fonseca
Journal:  J Mater Sci Mater Med       Date:  2014-01-22       Impact factor: 3.896

2.  Polyoxovanadates as new P-glycoprotein inhibitors: insights into the mechanism of inhibition.

Authors:  Diogo Henrique Kita; Gisele Alves de Andrade; Juliana Morais Missina; Kahoana Postal; Viktor Kalbermatter Boell; Francielli Sousa Santana; Ingrid Fatima Zattoni; Isadora da Silva Zanzarini; Vivian Rotuno Moure; Fabiane Gomes de Moraes Rego; Geraldo Picheth; Emanuel Maltempi de Souza; David A Mitchell; Suresh V Ambudkar; Giovana Gioppo Nunes; Glaucio Valdameri
Journal:  FEBS Lett       Date:  2021-12-30       Impact factor: 3.864

Review 3.  Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.

Authors:  Marianne Heibert Arnlind; Linda Fryklund; Sigurd Vitols; Göran Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2016-07-21       Impact factor: 2.953

Review 4.  Decavanadate Toxicology and Pharmacological Activities: V10 or V1, Both or None?

Authors:  M Aureliano
Journal:  Oxid Med Cell Longev       Date:  2016-01-21       Impact factor: 6.543

Review 5.  An update to the toxicological profile for water-soluble and sparingly soluble tungsten substances.

Authors:  Ranulfo Lemus; Carmen F Venezia
Journal:  Crit Rev Toxicol       Date:  2015-02-19       Impact factor: 5.635

6.  The P-type ATPase inhibiting potential of polyoxotungstates.

Authors:  Nadiia Gumerova; Lukáš Krivosudský; Gil Fraqueza; Joscha Breibeck; Emir Al-Sayed; Elias Tanuhadi; Aleksandar Bijelic; Juan Fuentes; Manuel Aureliano; Annette Rompel
Journal:  Metallomics       Date:  2018-02-21       Impact factor: 4.526

7.  Decavanadate Inhibits Mycobacterial Growth More Potently Than Other Oxovanadates.

Authors:  Nuttaporn Samart; Zeyad Arhouma; Santosh Kumar; Heide A Murakami; Dean C Crick; Debbie C Crans
Journal:  Front Chem       Date:  2018-11-20       Impact factor: 5.221

Review 8.  Vanadium Compounds as PTP Inhibitors.

Authors:  Elsa Irving; Andrew W Stoker
Journal:  Molecules       Date:  2017-12-19       Impact factor: 4.411

9.  Rationalizing the Decavanadate(V) and Oxidovanadium(IV) Binding to G-Actin and the Competition with Decaniobate(V) and ATP.

Authors:  Giuseppe Sciortino; Manuel Aureliano; Eugenio Garribba
Journal:  Inorg Chem       Date:  2020-11-30       Impact factor: 5.165

Review 10.  Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus.

Authors:  Samuel Treviño; Alfonso Díaz; Eduardo Sánchez-Lara; Brenda L Sanchez-Gaytan; Jose Manuel Perez-Aguilar; Enrique González-Vergara
Journal:  Biol Trace Elem Res       Date:  2018-10-22       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.